• Explore /
  • Poster
  • / Multiplexed autoantibody (AA) profiling of patients (pts) with metastatic urothelial carcinoma (mUC) receiving immune checkpoint inhibitors or platinum-based chemotherapy.

Multiplexed autoantibody (AA) profiling of patients (pts) with metastatic urothelial carcinoma (mUC) receiving immune checkpoint inhibitors or platinum-based chemotherapy.

Abstract Video & Slides Poster

Authors

Guru P. Sonpavde

Guru P. Sonpavde

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA

Guru P. Sonpavde , Dory Freeman , Elio Adib , Talal El Zarif , Jonathan Thomas , Pier Vitale Nuzzo , Arvind Ravi , Martha Tuff , Charlene Mantia , Bradley Alexander McGregor , Jacob E Berchuck , Petra Budde , Elena Rupieper , Jana Gajewski , Ronan McDaid , Ann-Sophie Schbuert , Manuel Bräutigam , Hans-Dieter Zucht , Praful Ravi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Translational Research, Tumor Biology, Biomarkers, and Pathology

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr 558)

DOI

10.1200/JCO.2022.40.6_suppl.558

Abstract #

558

Poster Bd #

K2

Abstract Disclosures

Similar Posters

First Author: Benjamin Miron

First Author: Haojie Li

First Author: Talal El Zarif

First Author: Rafael Morales-Barrera